Lv3
332 积分 2023-05-12 加入
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial
1个月前
已完结
Explainable machine learning framework for the molecular classification of triple negative breast cancer
1个月前
已完结
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
2个月前
已完结
Management of bone loss due to endocrine therapy during cancer treatment
2个月前
已完结
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
3个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
3个月前
已完结
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial
3个月前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
3个月前
已完结
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer
3个月前
已完结
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial
3个月前
已完结
皖公网安备34019202002308
